NEWS RELEASES

Date Title
Jul 3, 2019
Summary ToggleFDA Accepts New Drug Application for INSYS Therapeutics’ Naloxone Nasal Spray for the Emergency Treatment of Known or Suspected Opioid Overdose PHOENIX , July 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (OTCMKTS: INSYQ), announced today that its New Drug Application (NDA) to the U.S. Food and Drug Administration ( FDA ) for its investigational, proprietary naloxone nasal spray for the emergency treatment of known or suspected Printer Friendly Version
Jun 12, 2019
Summary ToggleINSYS Therapeutics, Inc. Receives Court Approval of “First Day” Motions Operations to Continue in the Ordinary Course During Court-Supervised Process PHOENIX , June 12, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY) (“INSYS” or the “Company”), a specialty pharmaceutical development and distribution company, announced that on June 11, 2019 INSYS Printer Friendly Version
Jun 10, 2019
Summary ToggleINSYS Therapeutics Initiates Court-Supervised Process to Facilitate Asset Sales and Address Legacy Liabilities Company to Facilitate Transaction Process and Sale of Substantially All Assets Through Chapter 11 of the U.S. Bankruptcy Code Operations to Continue as Normal Including Payment of Employee Wages and Benefits and Continuing Programs for Customers; Vendors and Suppliers to Receive Full Payment for Printer Friendly Version
May 10, 2019
Summary ToggleINSYS Therapeutics Reports First Quarter 2019 Results Company Continues to Execute Against Pipeline-Focused Strategy New Drug Application Submitted for Proprietary Naloxone Nasal Spray Formulation Company Provides Liquidity Update PHOENIX , May 10, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, Printer Friendly Version
Apr 15, 2019
Summary ToggleINSYS Therapeutics Implements Leadership Changes Andrew G. Long Appointed Chief Executive Officer PHOENIX , April 15, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that the Board of Directors has Printer Friendly Version
Mar 25, 2019
Summary ToggleINSYS Therapeutics to Present Poster of Pharmacokinetic Study of Naloxone Novel Nasal Spray at The College on Problems of Drug Dependence Annual Scientific Meeting PHOENIX , March 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the Company will present a poster of its pharmacokinetic (PK) study of its novel Printer Friendly Version
Mar 7, 2019
Summary ToggleINSYS Therapeutics Reports Fourth Quarter and Full Year 2018 Results Strategic Transformation Building Momentum with Two Planned NDAs in 2019 PHOENIX , March 07, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today reported financial Printer Friendly Version
Mar 6, 2019
Summary ToggleINSYS Therapeutics to Report Fourth Quarter and Full Year 2018 Results on March 7 PHOENIX , March 06, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced that it will release its fourth quarter and full year 2018 financial results on Printer Friendly Version
Feb 25, 2019
Summary ToggleINSYS Therapeutics Presented Poster of Initial Pharmacokinetic Study of Epinephrine Nasal Spray for the Emergency Treatment of Allergic Reactions (Type I) including Anaphylaxis at American Academy of Allergy, Asthma and Immunology Annual Meeting PHOENIX , Feb. 25, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, presented a poster of its initial pharmacokinetic (PK) study of comparative bioavailability of Printer Friendly Version
Jan 9, 2019
Summary ToggleINSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis Company’s Proprietary Formulation Continues to Show Promise as Potential Alternative to Intramuscular Injection PHOENIX , Jan. 09, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and Printer Friendly Version
Jan 3, 2019
Summary ToggleINSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference PHOENIX , Jan. 03, 2019 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, announced today that Saeed Motahari , president and chief executive officer, and Andy Long , chief Printer Friendly Version